PP Defence Therapeutics Related News
Defence Therapeutics applauds US President’s anti-cancer initiative
Defence Therapeutics Inc, a Canadian biotech company actively working on accelerating scientific discoveries an products development against cancer, congratulates US President, Joe Biden on...
Defence’s ACCUMTM variant “A1” converts mesenchymal stromal cells into potent antigen presenting cells
Defence Therapeutics has announced groundbreaking news about the development of a novel anti-cancer cellular vaccine using reprogrammed mesenchymal stromal cells.
Defence Therapeutics Inc., a Canadian...
Defence Therapeutics receives US patent for its ADC Platform Technology
In an exciting development, Defence Therapeutics has received a US patent covering its ADC Platform Technology.
In the latest announcement on August 8th, 2022, Defence...
ACCUTOXTM effectively eliminates cancer cells by eliciting DNA damage
In a potentially monumental breakthrough in the war against cancer, Defence Therapeutics has revealed that its leading AccuTOXTM compound effectively kills cancer cells through...
ACCUVAC-PTE7 cervical cancer vaccine provides complete protection
In a groundbreaking advancement in the treatment of cancer, Defence Therapeutics has revealed that the company’s AccuVAC-PTE7 cervical cancer vaccine completely protects against the...
Defence Therapeutics provides an update on its numerous anti-cancer projects
Biotechnology pioneers Defence Therapeutics outline its current research and development progress in a plethora of anti-cancer endeavours.
In Q1 of 2022, Defence signed an agreement...
Defence Therapeutics: Accelerating the fight against cancer and infectious diseases
Defence Therapeutics outlines how it is actively looking to continue the development of its product pipeline in partnership with large pharmaceutical companies.
Defence Therapeutics, a...
Defence Therapeutics move closer to AccuTOXTM Phase I clinical trial
Defence Therapeutics has established an agreement with CATO SMS, who will advise on submitting the company’s clinical application to Health Canada to initiate a...
Defence Therapeutics’ HPV vaccine achieves a higher humoral response than Gardasil-9
Canadian biotechnology company Defence Therapeutics has revealed that its novel HPV vaccine has demonstrated a higher humoral response than the Gardasil-9 vaccine.
The company’s new...
Defence Therapeutics achieves major milestone with anti-cancer molecule
Biotechnology company Defence Therapeutics has announced the start of its final step in GLP studies on its anti-cancer AccuTOXTM molecule at Eurofins Advinus Limited...
AccumTM platform greatly enhances CRISPR gene-editing technology
Defence Therapeutics has announced that its AccumTM platform can potently enhance Cas9 delivery in target cells, significantly advancing CRISPR gene-editing technology.
The CRISPR technology offers...
Defence Therapeutics: changing the face of vaccines using AccumTM technology
Biotechnology specialists Defence Therapeutics are changing the face of vaccines using its AccumTM technology to enable precise delivery of proteins of pharmacological interest to...
Defence Therapeutics: Optimising drug efficacy with AccumTM technology
Health Europa is excited to introduce the latest captivating eBook from industry pioneers of the biotechnology sector, Defence Therapeutics, who comprehensively elucidate their revolutionary...
Defence Therapeutics announces exciting addition to its board of directors
Biotechnology specialists Defence Therapeutics has revealed today that Dr Riam Shammaa has been appointed to its board of directors.
Dr Riam Shammaa, MD, is a...
Defence Therapeutics successfully test new COVID vaccine
Defence Therapeutics has sensationally revealed that they have successfully completed studies of their new COVID vaccine in a non-rodent rabbit model.
The innovative new COVID...
AccumTM variants successfully increase breast cancer treatment potency
Biotechnology experts Defence Therapeutics have revealed strong in vitro results of its AccumTM variants on the ADC breast cancer treatment called Enhertu® (fam-trastuzumab-deruxtecan-nxki), which...
Defence Therapeutics prepares to test its DC cancer vaccine against melanoma
Defence Therapeutics is finalising all required steps in preparation for a pre-IND meeting to initiate a phase I trial against melanoma using its DC cancer...
Defence Therapeutics embark on next stage of breast cancer treatment development
In a groundbreaking development, pioneering biotechnology company Defence Therapeutics has announced today it will be performing the final necessary studies before entering a Phase...
Defence Therapeutics’ new COVID vaccine achieves successful testing
Biotechnology experts Defence Therapeutics have sensationally announced that their new COVID vaccine has demonstrated effectiveness in a non-rodent model.
The new COVID vaccine – called...
Defence Therapeutics unveil novel HPV vaccine development programme
Industry-leading biotechnology company Defence Therapeutics has revealed that it will be establishing a high priority programme to develop a new HPV vaccine for cervical...
